NPLG event on March 5, 2020
NLPG invites its members to join us for this exciting evening event focusing on opportunities and challenges related to Nordic Life Science IPOs and biotech funding. For some life sciences businesses, but surely not for all, an IPO may be the best possible scenario to secure funding, but at what cost? Is the business perhaps run even better without being listed? What are the pitfalls and what other funding opportunities may be available?
Nasdaq, Carsten Borring (Head of Listings & Capital Markets) will present their perspectives on Nordic Life Science IPOs. What key learnings has Nasdaq had for the past decades, and which trends should businesses be aware of in the years to come? Virogates, Jakob Knudsen (CEO) has kindly agreed to provide us with their experience preparing for and being a listed company. An additional pharma company is expected to provide their thoughts on Nordic IPOs.
About Nasdaq The Copenhagen Stock Exchange or CSE (Københavns Fondsbørs), since 2014 officially called Nasdaq Copenhagen, is an international marketplace for Danish securities, including shares, bonds, treasury bills and notes, and financial futures and options. Nasdaq Copenhagen is one of the Nasdaq Nordic Exchanges. Nasdaq Nordic goes back to the 2003 merger of OM AB and HEX plc to form OMX and has, since February 2008, been part of Nasdaq, Inc. (formerly known as NASDAQ OMX Group).
About Virogates ViroGates was founded in 2001, based on an invention coming from Hvidovre Hospital, Denmark. Inventor and co-founder Jesper Eugen-Olsen discovered the utility of the biomarker suPAR in HIV. More than 600 publications have followed, substantiating suPAR as one of the most promising biomarker tools for various areas of healthcare. ViroGates has developed a product line called suPARnostic® to make the suPAR test commercially available, and the ambition is to get the test implemented and used for clinical decision making.